Revolution Medicines Q2 EPS $(0.92) Misses $(0.81) Estimate, Sales $3.82M Beat $1.56M Estimate
Portfolio Pulse from totan@benzinga.com
Revolution Medicines (NASDAQ:RVMD) reported Q2 losses of $(0.92) per share, missing the analyst consensus estimate of $(0.81) by 13.58%. This is a 12.2% decrease from the same period last year. However, the company's quarterly sales of $3.82 million beat the analyst consensus estimate of $1.56 million by 145.13%, despite a 58.05% decrease from last year.
August 08, 2023 | 8:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Revolution Medicines reported a larger than expected Q2 loss but beat sales estimates. This mixed report may lead to uncertain short-term price movements.
Revolution Medicines reported a larger than expected loss for Q2, which is typically a negative signal for investors and could put downward pressure on the stock. However, the company also reported higher than expected sales, which could offset some of this negative sentiment. The net impact on the stock price is uncertain in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100